Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

liraglitude

- PMLiVE

Saxenda debuts in US with $1,000-a-month price tag

It is the first market for Novo Nordisk’s obesity therapy

Making a difference with mobile health

Sanofi talks to PME about its latest mHealth initiative and tackling the diabetes epidemic

Bristol-Myers Squibb (BMS) building

BMS hails Opdivo and Yervoy combo in melanoma

New PD-1 therapy shines against the world’s first immunotherapy for skin cancer

- PMLiVE

AZ and Takeda drugs should carry heart failure warning

FDA panel claim diabetes drugs Onglyza and Nesina need label updates

Gilead Sciences

Sovaldi pushes Gilead to the top of US pharma list

Blockbuster hep c pill sees the firm go from fourteenth to first in just one year

- PMLiVE

AstraZeneca and PatientsLikeMe team up on real-world data

Two groups hoping to harness the power of the patient forum network

- PMLiVE

Novo Nordisk opens insulin facility in Russia

It will focus on new modern insulin formulation and filling

- PMLiVE

Going the distance

Sanofi’s Pascale Witz on driving through change

- PMLiVE

FDA starts review of Novo’s refiled diabetes pair

Tresiba and Ryzodeg were rejected in 2013

Bristol-Myers Squibb (BMS) building

BMS buys into gene therapy with $1bn uniQure alliance

US firm on a deal spree in 2015 as it racks up yet another collaboration

- PMLiVE

PD-1 cancer market overrated, says new report

The immuno-oncology market for new oncology drugs may be worth half of current expectations

- PMLiVE

Novo Nordisk will refile rejected diabetes duo in US

Danish firm hopes it will be second time lucky with key treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links